Arnaud Guille

Mr. Arnaud Guille

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
OCOlivier Cabaud
Olivier Cabaud
LBLudovic Berger
Ludovic Berger
ECEmerence Crompot
Emerence Crompot
JAJosé Adélaide
José Adélaide
PFPascal FINETTI
Pascal FINETTI
MLMarc Lopez
Marc Lopez
Antibody–drug conjugates (ADC) represent a fast-growing drug class in oncology. However, ADCs are associated with resistance, and therapies able to overcome it are of utmost importance. Recently, enfortumab vedotin-ejfv (EV) was approved in nectin-4+ metastatic urothelial cancer. We previously described PVRL4/nectin-4 as a new therapeutic target in breast cancer and produced an efficient EV-like ADC comprising a human anti–nectin-4 mAb conjugated to monomethyl auristatin-E (MMAE) named N41mab-vcMMAE. To study the consequence of the long-term treatment with this ADC, we developed a preclinical breast cancer model in mice, and report a mechanism of resistance to N41mab-vcMMAE after 9-month treatment and a way to reverse it. RNA-sequencing pointed to an upregulation in resistant tumors of ABCB1 expression, encoding the multidrug resistance protein MDR-1/P-glycoprotein (P-gp), associated with focal gene amplification and high protein expression. Sensitivity to N41mab-vcMMAE of the resistant model was restored in vitro by P-gp pharmacologic inhibitors, like tariquidar. P-gp is expressed in a variety of normal tissues. By delivering the drug to the tumor more specifically than classical chemotherapy, we hypothesized that the combined use of ADC with P-gp inhibitors might reverse resistance in vivo without toxicity. Indeed, we showed that the tariquidar/N41mab-vcMMAE combination was well tolerated and induced a rapid regression of ADC-resistant tumors in mice. In contrast, the tariquidar/docetaxel combination was toxic and poorly efficient. These results show that ABC transporter inhibitors can be safely used with ADC to reverse ADC-induced resistance and open new opportunities in the fight against multidrug resistance.

3 August 2022 in EMBO Molecular Medicine
Verified
Journal Article
Open access
ANAlexandre de Nonneville
Alexandre de Nonneville
SSSebastien Salas
Sebastien Salas
FBFrançois Bertucci
François Bertucci
ASAlexander P Sobinoff
Alexander P Sobinoff
JAJosé Adélaïde
José Adélaïde
VGVincent Géli
Vincent Géli
In some types of cancer, telomere length is maintained by the alternative lengthening of telomeres (ALT) mechanism. In many ALT cancers, the α‐thalassemia/mental retardation syndrome X‐linked (ATRX) gene is mutated leading to the conclusion that the ATRX complex represses ALT. Here, we report that most high‐grade pediatric osteosarcomas maintain their telomeres by ALT, and that the majority of these ALT tumors are ATRX wild‐type (wt) and instead carry an amplified 17p11.2 chromosomal region containing TOP3A. We found that TOP3A was overexpressed in the ALT‐positive ATRX‐wt tumors consistent with its amplification. We demonstrated the functional significance of these results by showing that TOP3A overexpression in ALT cancer cells countered ATRX‐mediated ALT inhibition and that TOP3A knockdown disrupted the ALT phenotype in ATRX‐wt cells. Moreover, we report that TOP3A is required for proper BLM localization and promotes ALT DNA synthesis in ALT cell lines. Collectively, our results identify TOP3A as a major ALT player and potential therapeutic target.

13 May 2019 in Cancers
Verified
Journal Article
Open access
PDF file
MTMarguerite Tyran
Marguerite Tyran
NCNadine Carbuccia
Nadine Carbuccia
SGSéverine Garnier
Séverine Garnier
AGArnaud Guille
Arnaud Guille
JAJosé Adelaïde
José Adelaïde
FBFrançois Bertucci
François Bertucci
Improving the systemic treatment of brain metastases (BM) in primary breast cancer (PBC) is impaired by the lack of genomic characterization of BM. To estimate the concordance of DNA copy-number-alterations (CNAs), mutations, and actionable genetic alterations (AGAs) between paired samples, we performed whole-genome array-comparative-genomic-hybridization, and targeted-next-generation-sequencing on 14 clinical PBC–BM pairs. We found more CNAs, more mutations, and higher tumor mutational burden, and more AGAs in BM than in PBC; 92% of the pairs harbored at least one AGA in the BM not observed in the paired PBC. This concerned various therapeutic classes, including tyrosine-kinase-receptor-inhibitors, phosphatidylinositol 3-kinase/AKT/ mammalian Target of Rapamycin (PI3K/AKT/MTOR)-inhibitors, poly ADP ribose polymerase (PARP)-inhibitors, or cyclin-dependent kinase (CDK)-inhibitors. With regards to the PARP-inhibitors, the homologous recombination defect score was positive in 79% of BM, compared to 43% of PBC, discordant in 7 out of 14 pairs, and positive in the BM in 5 out of 14 cases. CDK-inhibitors were associated with the largest percentage of discordant AGA appearing in the BM. When considering the AGA with the highest clinical-evidence level, for each sample, 50% of the pairs harbored an AGA in the BM not detected or not retained from the analysis of the paired PBC. Thus, the profiling of BM provided a more reliable opportunity, than that of PBC, for diagnostic decision-making based on genomic analysis. Patients with BM deserve an investigation of several targeted therapies.

27 June 2013 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
AGArnaud Guille
Arnaud Guille
MCMax CHAFFANET
Max CHAFFANET
DBDaniel Birnbaum
Daniel Birnbaum
Next generation sequencing studies have drawn the general landscape of breast cancers and identified hundreds of new, actual therapeutic targets. Two major signaling pathways seem to be altered in a vast proportion of breast cancers. The PI3 kinase/AKT pathway is activated and the JUN/MAPK pathway is repressed. Via the regulation of the cell cycle this metabolic switch impacts on the balance between self-renewal, proliferation and differentiation of the tumor-initiating cells

22 November 2024 in Briefings in Bioinformatics
Verified
Journal Article
Open access
AGArnaud Guille
Arnaud Guille
JAJosé Adélaïde
José Adélaïde
PFPascal FINETTI
Pascal FINETTI
FAFabrice Andre
Fabrice Andre
DBDaniel Birnbaum
Daniel Birnbaum
MCMax CHAFFANET
Max CHAFFANET
By identifying somatic mutations, whole-exome sequencing (WES) has become a technology of choice for the diagnosis and guiding treatment decisions in many cancers. Despite advances in the field of somatic variant detection and the emergence of sophisticated tools incorporating machine learning, accurately identifying somatic variants remains challenging. Each new somatic variant caller is often accompanied by claims of superior performance compared to predecessors. Furthermore, most comparative studies focus on a limited set of tools and reference datasets, leading to inconsistent results and making it difficult for laboratories to select the optimal solution. Our study comprehensively evaluated 20 somatic variant callers across four reference WES datasets. We subsequently assessed the performance of ensemble approaches by exploring all possible combinations of these callers, generating 8178 and 1013 combinations for single-nucleotide variants (SNVs) and indels, respectively, with varying voting thresholds. Our analysis identified five high-performing individual somatic variant callers: Muse, Mutect2, Dragen, TNScope, and NeuSomatic. For somatic SNVs, an ensemble combining LoFreq, Muse, Mutect2, SomaticSniper, Strelka, and Lancet outperformed the top-performing caller (Dragen) by >3.6% (mean F1 score = 0.927). Similarly, for somatic indels, an ensemble of Mutect2, Strelka, Varscan2, and Pindel outperformed the best individual caller (Neusomatic) by >3.5% (mean F1 score = 0.867). By considering the computational costs of each combination, we were able to identify an optimal solution involving four somatic variant callers, Muse, Mutect2, and Strelka for the SNVs and Mutect2, Strelka, and Varscan2 for the indels, enabling accurate and cost-effective somatic variant detection in whole exome.

3 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
EBEmilien BILLON
Emilien BILLON
GGGwenaelle Gravis
Gwenaelle Gravis
AGArnaud Guille
Arnaud Guille
NCNadine Carbuccia
Nadine Carbuccia
JAJose Adelaide
Jose Adelaide
FBFrançois Bertucci
François Bertucci
Introduction. The prognosis of advanced urological cancers (AUC) remains unfavorable, and few data are available regarding precision medicine. Methods: the PERMED-01 prospective clinical trial assessed the impact of molecular profiling in adults with refractory advanced solid cancer, in terms of number of patients with tumor actionable genetic alterations (AGA), feasibility, description of molecular alterations, treatment, and clinical outcome. We present here those results in the 64 patients enrolled with AUC. DNA extracted from a new tumor biopsy was profiled in real-time (targeted NGS, whole-genome array-comparative genomic hybridization), and the results were discussed during a weekly molecular tumor board meeting. Results: a complete molecular profile was obtained in 49 patients (77%). Thirty-eight (59%) had at least one AGA. Twelve (19%) received a matched therapy on progression, of which 42% had a PFS2/PFS1 ratio ≥ 1.3 versus 5% in the “non-matched therapy group” (n = 25). The objective response and disease control rates were higher in the “matched therapy group” (33% and 58%, respectively) than in the “non-matched therapy group” (13% and 22%), as was the 6-month OS (75% vs. 42%). Conclusion: the profiling of a newly biopsied tumor sample identified AGA in 59% of patients with AUC, led to “matched therapy” in 19%, and provided clinical benefit in 8%.